Media stories about Ocera Therapeutics (NASDAQ:OCRX) have been trending somewhat negative this week, Alpha One Sentiment reports. The research group, a subsidiary of Accern, identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ocera Therapeutics earned a news impact score of -0.12 on Alpha One’s scale. Alpha One also assigned media coverage about the biopharmaceutical company an impact score of 80 out of 100, indicating that recent news coverage is likely to have an impact on the stock’s share price in the near future.
A number of brokerages have recently commented on OCRX. Aegis reaffirmed a “buy” rating and issued a $3.00 target price on shares of Ocera Therapeutics in a report on Wednesday, May 24th. Zacks Investment Research cut shares of Ocera Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Ocera Therapeutics in a research note on Wednesday, May 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $3.90.
Ocera Therapeutics (OCRX) opened at 1.00 on Tuesday. Ocera Therapeutics has a 52 week low of $0.52 and a 52 week high of $3.15. The firm’s market capitalization is $26.51 million. The firm has a 50-day moving average of $1.12 and a 200 day moving average of $1.37.
Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.04. Ocera Therapeutics had a negative return on equity of 148.87% and a negative net margin of 4,416.26%. Analysts predict that Ocera Therapeutics will post ($1.10) earnings per share for the current year.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.